Mobius Therapeutics, ophthalmic surgery solutions company based in St. Louis, has announced that the Center for Medicare & Medicaid Services has given the company Outpatient Prospective Payment System Payment Indicator K2 for the reimbursement of Mitosol.
Hospitals and ASCs billing under OPPS will now be allowed payment for the Mitosol Kit for Ophthalmic Use.
Mitosol is designed to deliver antifibrotics during corneal, glaucoma and refractive surgeries.
More Articles on Ophthalmology:
MCRHS Eye Care Welcomes Dr. Elizabeth Garland
AAO Survey Finds US Ophthalmologists Foresee Negative Consequences of Medicare Cuts
Paragon BioTeck Names Dr. Paul Koch US Medical Advisor
Hospitals and ASCs billing under OPPS will now be allowed payment for the Mitosol Kit for Ophthalmic Use.
Mitosol is designed to deliver antifibrotics during corneal, glaucoma and refractive surgeries.
More Articles on Ophthalmology:
MCRHS Eye Care Welcomes Dr. Elizabeth Garland
AAO Survey Finds US Ophthalmologists Foresee Negative Consequences of Medicare Cuts
Paragon BioTeck Names Dr. Paul Koch US Medical Advisor